A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Fulvestrant (Primary) ; Ribociclib (Primary) ; Spartalizumab (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- 07 Nov 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 31 Aug 2018 Biomarkers information updated
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.